Filament Health Partners with TrPR Psychedelic Research Program at UCSF to Advance First Drug Candidates Through FDA Phase 1 and Phase 2 Clinical Trials

Natural psychedelic drug discovery and extraction company Filament Health has today announced a collaboration with UCSF’s recently-launched TrPR Program. TrPR, the Translational Psychedelic Research Program, is led by Dr. Joshua Woolley. The interdisciplinary network of researchers provides expertise spanning neuroscience, multiple medical specialties, nursing, and psychology. As part of the…

Source